These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
239 related articles for article (PubMed ID: 30693648)
1. Two cases of Hidradenitis suppurativa and botulinum toxin type a therapy: A novel approach for a pathology that is still difficult to manage. Campanati A; Martina E; Giuliodori K; Bobyr I; Consales V; Offidani A Dermatol Ther; 2019 May; 32(3):e12841. PubMed ID: 30693648 [TBL] [Abstract][Full Text] [Related]
2. Successful treatment of stage III hidradenitis suppurativa with botulinum toxin A. Shi W; Schultz S; Strouse A; Gater DR BMJ Case Rep; 2019 Jan; 12(1):. PubMed ID: 30665927 [TBL] [Abstract][Full Text] [Related]
3. Treatment of hidradenitis suppurativa with botulinum toxin A. O'Reilly DJ; Pleat JM; Richards AM Plast Reconstr Surg; 2005 Oct; 116(5):1575-6. PubMed ID: 16217533 [No Abstract] [Full Text] [Related]
4. Hidradenitis suppurativa in the pediatric population. Liy-Wong C; Pope E; Lara-Corrales I J Am Acad Dermatol; 2015 Nov; 73(5 Suppl 1):S36-41. PubMed ID: 26470613 [TBL] [Abstract][Full Text] [Related]
5. Botulinum Toxin Type B for Hidradenitis Suppurativa: A Randomised, Double-Blind, Placebo-Controlled Pilot Study. Grimstad Ø; Kvammen BØ; Swartling C Am J Clin Dermatol; 2020 Oct; 21(5):741-748. PubMed ID: 32761500 [TBL] [Abstract][Full Text] [Related]
6. Management of hidradenitis suppurativa. Drug Ther Bull; 2016 Sep; 54(9):102-5. PubMed ID: 27585997 [TBL] [Abstract][Full Text] [Related]
7. Botulinum Toxin in Hidradenitis Suppurativa: A Systematic Review. Ravi M; Trinidad J J Drugs Dermatol; 2022 Apr; 21(4):408-412. PubMed ID: 35389587 [TBL] [Abstract][Full Text] [Related]
8. Treatment of severe recalcitrant hidradenitis suppurativa with adalimumab. Harde V; Mrowietz U J Dtsch Dermatol Ges; 2009 Feb; 7(2):139-41. PubMed ID: 19371236 [TBL] [Abstract][Full Text] [Related]
9. Hidradenitis suppurativa treated with Clostridium botulinum toxin A. Khoo AB; Burova EP Clin Exp Dermatol; 2014 Aug; 39(6):749-50. PubMed ID: 24986398 [No Abstract] [Full Text] [Related]
10. Twenty-four-week interim analysis from a phase 3 open-label trial of adalimumab in Japanese patients with moderate to severe hidradenitis suppurativa. Morita A; Takahashi H; Ozawa K; Imafuku S; Nakama T; Takahashi K; Matsuyama T; Okubo Y; Kitamura S; Matsuda N; Zhao Y; Yokoyama M; Hayashi N; Terui T J Dermatol; 2019 Sep; 46(9):745-751. PubMed ID: 31282051 [TBL] [Abstract][Full Text] [Related]
11. Evidence-based approach to the treatment of hidradenitis suppurativa/acne inversa, based on the European guidelines for hidradenitis suppurativa. Gulliver W; Zouboulis CC; Prens E; Jemec GB; Tzellos T Rev Endocr Metab Disord; 2016 Sep; 17(3):343-351. PubMed ID: 26831295 [TBL] [Abstract][Full Text] [Related]
15. Adalimumab Treatment in Women With Moderate-to-Severe Hidradenitis Suppurativa from the Placebo-Controlled Portion of a Phase 2, Randomized, Double-Blind Study. Gottlieb A; Menter A; Armstrong A; Ocampo C; Gu Y; Teixeira HD J Drugs Dermatol; 2016 Oct; 15(10):1192-1196. PubMed ID: 27741335 [TBL] [Abstract][Full Text] [Related]
16. Hidradenitis suppurativa: A practical review of possible medical treatments based on over 350 hidradenitis patients. Scheinfeld N Dermatol Online J; 2013 Apr; 19(4):1. PubMed ID: 24021361 [TBL] [Abstract][Full Text] [Related]
17. The pharmacology of antibiotic therapy in hidradenitis suppurativa. Marasca C; Tranchini P; Marino V; Annunziata MC; Napolitano M; Fattore D; Fabbrocini G Expert Rev Clin Pharmacol; 2020 May; 13(5):521-530. PubMed ID: 32364806 [TBL] [Abstract][Full Text] [Related]